Insmed在鼻窦炎中放弃brensocatib后下降

2025-12-18 06:33

Insmed (INSM) is down ~17% in after-hours trading Monday after saying it will end development of brensocatib for chronic rhinosinusitis without nasal polyps after the candidate failed to meet primary and secondary endpoints in a phase 2b study.
The study enrolled 288 patients who were randomize to receive either brensocatib 10 mg, brensocatib 40 mg, or placebo (n=95) daily for 24 weeks in addition to daily mometasone furoate nasal spray background therapy.
The primary endpoint was change from baseline in the 28-day average of daily sTSS (Sinus Total Symptom Score) at week 24. In the 10 mg and 40 mg groups, the figures were, respectively, -2.21 and -2.33. In the placebo cohort, it was -2.44.
Insmed noted that no new safety signals were identified.
Brensocatib is also in phase 2 for hidradenitis suppurativa. It is marketed for non-cystic fibrosis bronchiectasis under the name Brinsupri.

More on Insmed